Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Tesaro, Inc.
Sotio Biotech Inc.
Pfizer
Alaunos Therapeutics
Tempus AI
Incyte Corporation
Virginia Commonwealth University
M.D. Anderson Cancer Center
Institut Bergonié
Mural Oncology, Inc
Masonic Cancer Center, University of Minnesota
Herlev Hospital
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
Numab Therapeutics AG
Mayo Clinic
Pfizer
Thomas Jefferson University
Stanford University
NextCure, Inc.
M.D. Anderson Cancer Center
University of Southern California
Brown University
Elevation Oncology
Mateon Therapeutics
North Eastern German Society of Gynaecological Oncology
Columbia University
Deciphera Pharmaceuticals, LLC
Jazz Pharmaceuticals
Astellas Pharma Inc
Five Prime Therapeutics, Inc.
Pfizer
AbbVie
Baylor College of Medicine
Merck Sharp & Dohme LLC
NantCell, Inc.
University of Pittsburgh
NantCell, Inc.
ModernaTX, Inc.
Pfizer
NextCure, Inc.
University of Miami
ADC Therapeutics S.A.
Sumitomo Pharma America, Inc.
Pfizer
Henry Ford Health System
Fox Chase Cancer Center